Statin discontinuation after coronary revascularization
K Yamamoto, T Morimoto, M Natsuaki, H Shiomi… - The American Journal of …, 2023 - Elsevier
There is a scarcity of studies evaluating statin discontinuation in patients with coronary artery
disease in real-world practice. In 11,144 patients who underwent first coronary …
disease in real-world practice. In 11,144 patients who underwent first coronary …
Statins in primary prevention in people over 80 years
In the much older population (≥ 80 years), the management of cardiovascular diseases
requires specific research to avoid a plain transposition of medical practice from younger …
requires specific research to avoid a plain transposition of medical practice from younger …
The need for clinical judgement in the application of evidence-based medicine
JD Spence - BMJ Evidence-Based Medicine, 2020 - ebm.bmj.com
Background Evidence-based medicine (EBM) has no doubt resulted in great improvements
in the practice of medicine. However, there are problems with overly zealous application of …
in the practice of medicine. However, there are problems with overly zealous application of …
State of the art: statin therapy
U Laufs, O Weingaertner, U Kassner… - Deutsche Medizinische …, 2021 - europepmc.org
Atorva-, Simva-und Lovastatin werden primär über das Cytochrom-P450-System 3A4 der
Leber metabolisiert. Inhibitoren des CYP3A4-Systems erhöhen die Spiegel und damit das …
Leber metabolisiert. Inhibitoren des CYP3A4-Systems erhöhen die Spiegel und damit das …
Effect of rosuvastatin 20 mg versus rosuvastatin 5 mg plus ezetimibe on statin side-effects in elderly patients with atherosclerotic cardiovascular disease: Rationale …
JJ Cha, SJ Hong, JH Kim, S Lim, HJ Joo, JH Park… - American Heart …, 2023 - Elsevier
Background Current guidelines recommend that patients with established atherosclerotic
cardiovascular disease (ASCVD) use high-intensity statin therapy to lower low-density …
cardiovascular disease (ASCVD) use high-intensity statin therapy to lower low-density …
[HTML][HTML] Different perspectives of patients and physicians on LDL-C target achievement in the treatment of hypercholesterolemia: results on secondary prevention from …
U Makhmudova, M Wolf, K Willfeld, L Beier… - Advances in …, 2023 - Springer
Aims Low-density lipoprotein cholesterol (LDL-C) reduction in hypercholesterolemia
patients at very high cardiovascular (CV) risk is essential in preventing future CV events. The …
patients at very high cardiovascular (CV) risk is essential in preventing future CV events. The …
Aspirin and statin therapy for primary prevention of cardiovascular disease in older adults
S Montgomery, MD Miedema, JA Dodson - Heart, 2022 - heart.bmj.com
The value of primary preventative therapies for cardiovascular disease (CVD) in older adults
(age≥ 75 years) is less certain than in younger patients. There is a lack of quality evidence …
(age≥ 75 years) is less certain than in younger patients. There is a lack of quality evidence …
Statin use in older adults with stable atherosclerotic cardiovascular disease
G Spencer‐Bonilla, S Chung, A Sarraju… - Journal of the …, 2021 - Wiley Online Library
Background/Objectives Older adults (> 75 years of age) represent two‐thirds of
atherosclerotic cardiovascular disease (ASCVD) deaths. The 2013 and 2018 American multi …
atherosclerotic cardiovascular disease (ASCVD) deaths. The 2013 and 2018 American multi …
[HTML][HTML] Do statins reduce mortality in older people? Findings from a longitudinal study using primary care records
LA Gitsels, I Bakbergenuly, N Steel… - Family Medicine and …, 2021 - ncbi.nlm.nih.gov
Do statins reduce mortality in older people? Findings from a longitudinal study using
primary care records - PMC Back to Top Skip to main content NIH NLM Logo Access keys …
primary care records - PMC Back to Top Skip to main content NIH NLM Logo Access keys …
Diversity is richness: why data reporting according to sex, age, and ethnicity matters
TF Lüscher, VM Miller, CN Bairey Merz… - European heart …, 2020 - academic.oup.com
Traditionally, data have been reported for the entire patient population of a given study,
registry or trial. If subgroups have been further investigated, they typically involved …
registry or trial. If subgroups have been further investigated, they typically involved …